Trial Profile
Randomized Phase II trial of Neoadjuvant weekly Nab-paclitaxel followed by FEC compared with Docetaxel followed by FEC for early breast cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Apr 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
- Indications Early breast cancer
- Focus Therapeutic Use
- 27 Sep 2015 Results presented at the ASCO - Breast Cancer Symposium 2015
- 03 Jun 2011 New trial record